|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0011306,
umls-concept:C0021743,
umls-concept:C0030705,
umls-concept:C0205210,
umls-concept:C0332307,
umls-concept:C0439662,
umls-concept:C0870134,
umls-concept:C1274040,
umls-concept:C1321872,
umls-concept:C1332710,
umls-concept:C1441547,
umls-concept:C1519885,
umls-concept:C1879547
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2005-8-22
|
|
pubmed:abstractText |
Twenty-two HLA A*0201 patients with stage IV melanoma were enrolled in a phase 1 safety and feasibility trial using a composite dendritic cell (DC) vaccine generated by culturing CD34 hematopoietic progenitors and activated with IFN-alpha. The DC vaccine was loaded with peptides derived from four melanoma tissue differentiation antigens (MART-1, tyrosinase, MAGE-3, and gp100) and influenza matrix peptide (Flu-MP). Twenty patients were evaluable, 14 of whom received vaccination with peptide-pulsed DCs without keyhole limpet hemocyanin (KLH) and 6 of whom received vaccination with KLH-loaded DCs. Patients were vaccinated until disease progression or until they had received eight vaccinations. None of the analyzed patients showed the expansion of melanoma-peptide-specific circulating effector memory T cells that secrete IFN-gamma in direct ELISPOT. Melanoma-peptide-specific recall memory CD8 T cells able to secrete IFN-gamma and to proliferate could be detected in six of the seven analyzed patients. There were no objective clinical responses. The estimated median overall survival was 12 months (range 2-38), and the median event-free survival was 4 months (range 1-12). There was no statistically significant survival advantage in patients who received KLH-loaded vaccines. As of March 2005, four patients remained alive, 26+, 28+, 28+, and 36+ months. Three of them had received KLH-loaded vaccines and all of them had had additional therapy. Overall, these results suggest that IFN-alpha-activated CD34-DCs are safe but elicit only limited immune responses, underscoring the need to test different DC maturation factors.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD34,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A*02:01 antigen,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A2 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon Type I,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/MAGEA3 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/MART-1 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/MLANA protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Monophenol Monooxygenase,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/SILV protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Matrix Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/gp100 Melanoma Antigen
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1524-9557
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
505-16
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16113607-Adult,
pubmed-meshheading:16113607-Antigens, CD34,
pubmed-meshheading:16113607-Antigens, Neoplasm,
pubmed-meshheading:16113607-Cancer Vaccines,
pubmed-meshheading:16113607-Cell Proliferation,
pubmed-meshheading:16113607-Dendritic Cells,
pubmed-meshheading:16113607-Disease Progression,
pubmed-meshheading:16113607-Disease-Free Survival,
pubmed-meshheading:16113607-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:16113607-HLA-A Antigens,
pubmed-meshheading:16113607-HLA-A2 Antigen,
pubmed-meshheading:16113607-Humans,
pubmed-meshheading:16113607-Immunotherapy, Adoptive,
pubmed-meshheading:16113607-Influenza A virus,
pubmed-meshheading:16113607-Interferon Type I,
pubmed-meshheading:16113607-Interferon-alpha,
pubmed-meshheading:16113607-Interferon-gamma,
pubmed-meshheading:16113607-MART-1 Antigen,
pubmed-meshheading:16113607-Melanoma,
pubmed-meshheading:16113607-Membrane Glycoproteins,
pubmed-meshheading:16113607-Middle Aged,
pubmed-meshheading:16113607-Monophenol Monooxygenase,
pubmed-meshheading:16113607-Neoplasm Proteins,
pubmed-meshheading:16113607-Peptide Fragments,
pubmed-meshheading:16113607-Peptides,
pubmed-meshheading:16113607-Stem Cells,
pubmed-meshheading:16113607-Time Factors,
pubmed-meshheading:16113607-Treatment Outcome,
pubmed-meshheading:16113607-Viral Matrix Proteins,
pubmed-meshheading:16113607-gp100 Melanoma Antigen
|
|
pubmed:articleTitle |
Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon.
|
|
pubmed:affiliation |
Baylor Institute for Immunology Research, Dallas, TX, USA. jacquesb@baylorhealth.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I,
Research Support, N.I.H., Extramural
|
